Classical Swine Fever: A Truly Classical Swine Disease

Wang, Fun-In; Chang, Chia‐Yi

doi:10.3390/pathogens9090745

Cited by 2 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding cross-protectivity of CSFV vaccines, it has been shown that the C-strain vaccine and the LPC G1-based vaccines could prevent the circulation of most G1 CSFVs in the world and reduce the incidences of G3.2 CSFV in Korea, G3.3 CSFV in Thailand, and G3.4 CSFV in Japan and Taiwan ( 36 , 37 , 53 ). The tissue-adapted version of the C-stain vaccine Riemser vaccine has also been demonstrated to provide complete protection against G2.1 and G3.3, and G2.1c CSFVs ( 8 , 38 ). However, we have demonstrated herein that hyperimmune serum from CSFV E2 glycoprotein-immunized mice exhibited better neutralizing abilities against homologous CSFV than heterogeneous viruses.…”

Section: Discussionmentioning

confidence: 99%

“…Even though areas can be declared CSF-free, the re-emergence of CSF and emergence of new sub-genotypes of classical swine fever virus (CSFV) have been reported ( 6 ). In Japan, outbreaks of G2.1d CSFV in pig farms and wild boars in Gifu City in 2018 were re-emerged after 26 years of CSF-free status ( 6 – 8 ) indicating the difficulty in eradication of the disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cross-reactivities and cross-neutralization of different envelope glycoproteins E2 antibodies against different genotypes of classical swine fever virus

et al. 2023

Self Cite

View full text Add to dashboard Cite

Classical swine fever (CSF) is a highly contagious swine disease caused by the classical swine fever virus (CSFV), wreaking havoc on global swine production. The virus is divided into three genotypes, each comprising 4–7 sub-genotypes. The major envelope glycoprotein E2 of CSFV plays an essential role in cell attachment, eliciting immune responses, and vaccine development. In this study, to study the cross-reaction and cross-neutralizing activities of antibodies against different genotypes (G) of E2 glycoproteins, ectodomains of G1.1, G2.1, G2.1d, and G3.4 CSFV E2 glycoproteins from a mammalian cell expression system were generated. The cross-reactivities of a panel of immunofluorescence assay-characterized serum derived from pigs with/without a commercial live attenuated G1.1 vaccination against different genotypes of E2 glycoproteins were detected by ELISA. Our result showed that serum against the LPCV cross-reacted with all genotypes of E2 glycoproteins. To evaluate cross-neutralizing activities, hyperimmune serum from different CSFV E2 glycoprotein-immunized mice was also generated. The result showed that mice anti-E2 hyperimmune serum exhibited better neutralizing abilities against homologous CSFV than heterogeneous viruses. In conclusion, the results provide information on the cross-reactivity of antibodies against different genogroups of CSFV E2 glycoproteins and suggest the importance of developing multi-covalent subunit vaccines for the complete protection of CSF.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cross-reactivities and cross-neutralization of different envelope glycoproteins E2 antibodies against different genotypes of classical swine fever virus

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Live attenuated C-strain CSFV vaccines provide complete protection in at least seven days, but the lack of DIVA is problematic for eradication programs in CSF enzootic areas [ 4 ]. Some live attenuated vaccines also carry genuine concerns over their safety, due to the potential of reversion to virulence and recombination with pathogens in the field [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus

et al. 2021

View full text Add to dashboard Cite

Live attenuated C-strain classical swine fever vaccines provide early onset protection. These vaccines confer effective protection against the disease at 5–7 days post-vaccination. It was previously reported that intramuscular administration of the Porvac® vaccine protects against highly virulent classical swine fever virus (CSFV) “Margarita” strain as early as seven days post-vaccination. In order to identify how rapidly protection against CSFV is conferred after a single dose of the Porvac® subunit vaccine E2-CD154, 15 swine, vaccinated with a single dose of Porvac®, were challenged intranasally at five, three, and one day post-vaccination with 2 x 103 LD50 of the highly pathogenic Cuban “Margarita” strain of the classical swine fever virus. Another five animals were the negative control of the experiment. The results provided clinical and virological data confirming protection at five days post-vaccination. Classical swine fever (CSF)-specific IFNγ T cell responses were detected in vaccinated animals but not detected in unvaccinated control animals. These results provided the first data that a subunit protein vaccine demonstrates clinical and viral protection at five days post-vaccination, as modified live vaccines.

show abstract

Classical Swine Fever: A Truly Classical Swine Disease

Abstract: Recent reemergence of classical swine fever (CSF) in previous CSF-free areas reminds the veterinary community of this old disease [...]

Cited by 2 publications

References 18 publications

Cross-reactivities and cross-neutralization of different envelope glycoproteins E2 antibodies against different genotypes of classical swine fever virus

Cross-reactivities and cross-neutralization of different envelope glycoproteins E2 antibodies against different genotypes of classical swine fever virus

Porvac® Subunit Vaccine E2-CD154 Induces Remarkable Rapid Protection against Classical Swine Fever Virus

Contact Info

Product

Resources

About